ClinicalTrials.gg
Not yet recruitingNCT07494903Updated Mar 27, 2026

Effects of Vibrational Therapy on Pelvic Floor Muscle Strength and Tone in Healthy Women

An interventional study of High frequency vibration group and Moderate frequency vibration group in Healhty, sponsored by Universidad Europea de Madrid. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Universidad Europea de Madrid · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This quasi-experimental study aims to evaluate the effects of mechanical vibration applied to the pelvic floor musculature in healthy women aged 18-45. The intervention involves vibrational therapy targeting the central fibrous nucleus of the perineum, with the goal of assessing changes in muscle tone, strength, and biomechanical properties. The study will also examine the tolerance to this technique, with data collected at baseline and after 8 weeks of treatment.

Read the detailed description

his study investigates the effects of mechanical vibration applied to the pelvic floor musculature in healthy women aged 18 to 45 years. The intervention involves applying vibrational therapy to the central fibrous nucleus of the perineum, with the objective of assessing its impact on muscle tone, strength, and biomechanical properties such as rigidity, elasticity, and muscle stiffness. The study will also explore the tolerance of participants to this therapeutic technique.

The study follows a quasi-experimental design with a blinded evaluator. A total of 60 participants will be randomly assigned to one of four groups: three intervention groups receiving vibration at different frequencies (138 Hz, 41.5 Hz, and 24.9 Hz), and one control group receiving no intervention. The intervention will be administered twice a week for 8 weeks, with each session lasting 20 minutes.

Primary outcomes include changes in the tone and strength of the pelvic floor muscles, measured using various instruments such as the MyotonPro® for biomechanical parameters, the IEase XFT0010 for manometric measurements, and the Pelvimeter Phénix for dynamometry. Secondary outcomes include the evaluation of the vibration's impact on muscle elasticity, rigidity, and other biomechanical properties, as well as the participant's tolerance to the treatment.

The study is conducted in compliance with ethical principles set out in the Declaration of Helsinki, and participant data will be handled confidentially according to data protection regulations. The results of this research may contribute valuable insights into non-invasive treatments for pelvic floor dysfunctions, which are common in women and often impact their physical and mental well-being

02

Conditions studied

  • Healhty
03

In context

Lead sponsor

Universidad Europea de Madrid is the lead sponsor of 99 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Throughout the intervention (ongoing during each session) and Post-intervention (after 8 weeks of treatment).

Exclusion criteria

Exclusion Criteria:

  • 1. Urogenital Infections: Presence of any active urogenital infections. 2. Abdominal or Pelvic Surgery: History of abdominal or pelvic surgery. 3. Active Menstruation: Women who are menstruating at the time of the study. 4. Breastfeeding: Participants who are actively breastfeeding. 5. Mictrurition Symptoms: Presence of any urinary symptoms. 6. Pain: Pain upon palpation of the central fibrous nucleus of the perineum. 7. Sensory Alterations: Presence of altered sensitivity such as hypoalgesia, hyperalgesia, or allodynia.

    8. Spinal Lesions: History of spinal cord injuries. 9. Neurological Conditions: Any neurological disorders. 10. Pelvic Organ Prolapse: Diagnosed prolapse of pelvic organs. 11. Obesity: (BMI) ≥ 30 kg/m². 12. Active Oncology Treatment: Any current or recent cancer treatments. 13. Pregnancy: Women who are pregnant. 14. Pelvic Floor Pathologies: Diagnosed pelvic floor dysfunctions. 15. Ongoing Pelvic Floor Treatment: Participants currently receiving active pelvic floor treatments.

    16. Dermatological Pathologies: Any active vulvar dermatological conditions.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High frequency vibration group

    Participants in this group will receive mechanical vibration applied to the central fibrous nucleus of the perineum at a frequency of 138 Hz. The treatment will be administered twice a week for 8 weeks, with each session lasting 20 minutes. The primary aim is to evaluate the effects of high-frequency vibration on the tone, strength, and biomechanical properties of the pelvic floor muscles.

    Other: High frequency vibration group

  • Active comparator
    Moderate frequency vibration group

    Participants in this group will receive mechanical vibration applied to the central fibrous nucleus of the perineum at a frequency of 41.5 Hz. The treatment will be administered twice a week for 8 weeks, with each session lasting 20 minutes. The focus is to assess the effects of moderate-frequency vibration on the muscle tone, strength, and biomechanical parameters of the pelvic floor musculature

    Other: Low frequency vibration group

  • Experimental
    Low frequency vibration group

    Participants in this group will receive mechanical vibration applied to the central fibrous nucleus of the perineum at a frequency of 24.9 Hz. The treatment will be administered twice a week for 8 weeks, with each session lasting 20 minutes. The goal is to evaluate how low-frequency vibration impacts the pelvic floor muscle tone, strength, and biomechanical properties compared to the other groups.

    Other: Moderate frequency vibration group

Interventions

  • OtherHigh frequency vibration group

    z. The treatment will be administered twice a week for 8 weeks, with each session lasting 20 minutes. The primary aim is to evaluate the effects of high-frequency vibration on the tone, strength, and biomechanical properties of the pelvic floor muscles.

  • OtherModerate frequency vibration group

    Participants in this group will receive mechanical vibration applied to the central fibrous nucleus of the perineum at a frequency of 41.5 Hz. The treatment will be administered twice a week for 8 weeks, with each session lasting 20 minutes. The focus is to assess the effects of moderate-frequency vibration on the muscle tone, strength, and biomechanical parameters of the pelvic floor musculature

  • OtherLow frequency vibration group

    Participants in this group will receive mechanical vibration applied to the central fibrous nucleus of the perineum at a frequency of 24.9 Hz. The treatment will be administered twice a week for 8 weeks, with each session lasting 20 minutes. The goal is to evaluate how low-frequency vibration impacts the pelvic floor muscle tone, strength, and biomechanical properties compared to the other groups.

06

What researchers measure

Primary outcomes

  1. Pelvic floor muscle tone

    The tone of the pelvic floor muscles will be measured using the MyotonPro® device, which assesses the frequency of oscillation (Hz) of the muscle. The tone will be evaluated at baseline and post-intervention to determine any changes resulting from the vibrational therapy.

    Time frame: Baseline (before intervention) and Post-intervention (after 8 weeks of treatment).

Secondary outcomes

  1. Pelvic floor muscle strength

    Pelvic floor muscle strength will be assessed using two methods: Manometry (with the IEase XFT0010) to measure the pressure in mmHg during voluntary contraction, and Dynamometry (with the Pelvimeter Phénix) to measure force in Newtons (N) during vaginal contraction. These assessments will help evaluate changes in the muscle's ability to contract before and after the intervention.

    Time frame: Baseline (before intervention) and Post-intervention (after 8 weeks of treatment).

  2. Biomechanical properties of pelvic floor musculature

    Biomechanical properties such as muscle rigidity (N/m), elasticity (logarithmic decrement), and fluency (number of Deborah) will be measured using the MyotonPro®. This will help evaluate changes in the muscle's stiffness and viscoelastic properties resulting from the vibrational therapy.

    Time frame: Baseline (before intervention) and Post-intervention (after 8 weeks of treatment)

  3. Pelvic floor dysfunction impact

    The Pelvic Floor Distress Inventory (PFDI-20) questionnaire will be administered to measure the degree of pelvic floor dysfunction symptoms and their impact on the participant's daily life. This includes symptoms related to urinary incontinence, pelvic organ prolapse, and other pelvic health issues

    Time frame: Baseline (before intervention) and Post-intervention (after 8 weeks of treatment).

  4. Tolerance to the vibration therapy

    Participants will be asked to rate their tolerance to the vibration therapy, including any discomfort or adverse effects experienced during the intervention. This will be recorded to assess the safety and acceptability of the treatment.

    Time frame: Throughout the intervention (ongoing during each session) and Post-intervention (after 8 weeks of treatment).

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lee J, Lee K, Song C. Determining the Posture and Vibration Frequency that Maximize Pelvic Floor Muscle Activity During Whole-Body Vibration. Med Sci Monit. 2016 Oct 27;22:4030-4036. doi: 10.12659/msm.898011. PubMed 27787476 ↗
  • Rodrigues MP, Paiva LL, Ramos JGL, Ferla L. Vibratory perineal stimulation for the treatment of female stress urinary incontinence: a systematic review. Int Urogynecol J. 2018 Apr;29(4):555-562. doi: 10.1007/s00192-017-3444-y. Epub 2017 Aug 15. PubMed 28812109 ↗
  • Barassi G, Bellomo RG, Frondaroli F, Frondaroli S, Santarelli A, Di Felice PA, Supplizi M, Palermo T, Saggini R. Integrated Rehabilitation Approach with Manual and Mechanic-Acoustic Vibration Therapies for Urinary Incontinence. Adv Exp Med Biol. 2019;1211:41-50. doi: 10.1007/5584_2019_436. PubMed 31468357 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 27, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07494903
Lead sponsor
Universidad Europea de Madrid
Responsible party
Carlos Romero Morales (Full Professor, Universidad Europea de Madrid) — Principal investigator
First posted
Mar 27, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Carlos Romero PhD, PhD
Contact
carlos.romero@universidadeuropea.es
+34696879745

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion